Lineage Cell Therapeutics...

AMEX: LCTX · Real-Time Price · USD
1.26
0.24 (23.53%)
At close: Aug 15, 2025, 1:08 PM

Lineage Cell Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
9.5M 8.95M 14.7M 3.9M
Cost of Revenue
334K 671K 728K 1.43M
Gross Profit
9.16M 8.27M 13.97M 2.47M
Operating Income
-21.48M -24.73M -22.52M -49.21M
Interest Income
1.72M 1.63M 829K 2K
Pretax Income
-18.58M -23.28M -25.81M -43.27M
Net Income
-18.61M -21.49M -26.35M -43.02M
Selling & General & Admin
18.17M 17.3M 22.51M 18.21M
Research & Development
12.47M 15.71M 13.99M 33.91M
Other Expenses
n/a n/a n/a -445K
Operating Expenses
30.64M 33.01M 36.49M 51.68M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
30.98M 33.68M 37.22M 53.11M
Income Tax Expense
27K -1.8M 541K -4.71M
Shares Outstanding (Basic)
200.19M 172.66M 169.79M 164.5M
Shares Outstanding (Diluted)
200.19M 172.66M 169.79M 164.5M
EPS (Basic)
-0.09 -0.12 -0.15 -0.26
EPS (Diluted)
-0.09 -0.12 -0.15 -0.26
EBITDA
-20.87M -24.04M -21.79M -48.34M
EBIT
-21.48M -24.73M -22.52M -49.21M
Depreciation & Amortization
609K 692K 727K 887K